PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, ...

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed ...

Vaxcyte, Inc. (NASDAQ:PCVX) is currently advancing to the second stage of the ongoing phase 2 study evaluating VAX-31 for the prevention of invasive pneumococcal disease in infants.

Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses ...

This agreement supports the potential global commercialization of Vaxcyte’s PCV candidates in both the adult and pediatric populations and complements Vaxcyte’s plans to utilize existing Lonza ...

The firm maintains an Outperform rating on Vaxcyte shares, which are down $34.89, or 50%, to $34.57 in early afternoon trading following the company having shared topline results from its Phase 2 ...

Vaxcyte's shares surged as much as 48% to a record high on Tuesday after the company said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety ...

Vaxcyte Inc.’s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.

Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the ...

Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations (1) ...